BIIB vs PKX Comparison

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

POSCO Holdings Inc is a holding company operating through its subsidiaries. Its business is divided into segments, with the Steel segment generating the majority of revenue from the manufacture and sale of steel products. The Infrastructure segment includes trading, construction, and logistics and system integration activities. The Rechargeable Battery Materials segment focuses on EV battery materials such as lithium, nickel, and cathode and anode materials. The Others segment includes the controlling company and investment business. Geographically, the Group generates majority of its revenue from Asia (excluding China and Japan).